Stevanato Group SpA

As of October 31, 2025, Stevanato Group SpA's trend is mildly bullish with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of October 31, 2025, Stevanato Group SpA's technical trend is mildly bullish, with mixed signals from indicators like the MACD and KST, while it has underperformed the S&P 500 recently but outperformed on a year-to-date basis.

As of October 31, 2025, Stevanato Group SpA's technical trend is mildly bullish, with mixed signals from indicators like the MACD and Bollinger Bands, despite recent underperformance against the S&P 500.

As of October 31, 2025, Stevanato Group SpA shows a mildly bullish technical trend, supported by daily moving averages and monthly Bollinger Bands, despite mixed signals from MACD indicators and recent underperformance compared to the S&P 500.

As of September 3, 2025, Stevanato Group SpA shows a mildly bullish trend supported by strong MACD and Bollinger Bands indicators, despite mixed signals from KST and Dow Theory, and has significantly outperformed the S&P 500 over the past month and year.

As of June 30, 2025, Stevanato Group SpA is considered attractive and potentially undervalued with a P/E ratio of 47 and strong performance, outperforming the S&P 500, while offering better value compared to peers like TransMedics and LeMaitre Vascular.

As of May 9, 2024, Stevanato Group SpA is considered overvalued with a high P/E ratio of 47 and an EV to EBITDA ratio of 26.56, despite a strong 1-year return of 31.76%.

As of June 20, 2025, the trend is mildly bullish with positive indicators like a bullish MACD and RSI, but mixed signals from the KST and OBV suggest underlying weakness.

Stevanato Group SpA is a mid-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $270 million and a net profit of $28 million. Key metrics include a P/E ratio of 47.00 and a market cap of approximately $6.58 billion.

As of Jun 18, Stevanato Group SpA has a market capitalization of 6,576.86 million, with net sales of 1,207.41 million and a net profit of 134.59 million for the latest four quarters. The balance sheet shows shareholder's funds of 1,454.19 million and total assets of 2,411.49 million.